Viridian Therapeutics (VRDN)
NASDAQ:VRDN
Holding VRDN?
Track your performance easily

Viridian Therapeutics (VRDN) Ownership - Who Owns Viridian Therapeutics?

1,036 Followers

Viridian Therapeutics (VRDN) Ownership Overview

33.29%24.44%12.73%29.54%
33.29% Insiders
12.73% Other Institutional Investors
― ETFs
29.54% Public Companies and
Individual Investors
The ownership structure of Viridian Therapeutics (VRDN) stock is a mix of institutional, retail, and individual investors. , 33.29% is owned by Insiders, and 29.54% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Jan 24, 2024
Fairmount Funds Management Llc
Director, >10% Owner
xxxxxxxxxxxxx
$9999990

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Mar 31, 2024
xxxxxxxxxxxxx
$6812913
Mar 31, 2024
xxxxxxxxxxxxx
$7685524
Mar 31, 2024
xxxxxxxxxxxxx
$32320185
Mar 31, 2024
xxxxxxxxxxxxx
$47144169

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
3,657,099Institution5.73%53,722,784
2,993,201Institution4.69%43,970,123
2,692,414Institution4.22%39,551,562
2,614,246Institution4.10%38,403,274
2,466,672Institution3.86%36,235,412
2,219,238Institution3.48%32,600,606
2,203,641Institution3.45%32,371,486
2,034,907Institution3.19%29,892,784
2,007,946Institution3.15%29,496,727
1,845,813Institution2.89%27,114,993

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
2,614,246Institution4.10%38,403,274
2,219,238Institution3.48%32,600,606
2,203,641Institution3.45%32,371,486
2,034,907Institution3.19%29,892,784
994,594Institution1.56%14,610,586
891,862Institution1.40%13,101,453
779,911Institution1.22%11,456,893
672,500Institution1.05%9,879,025
525,405Institution0.82%7,718,199
464,240Institution0.73%6,819,686

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,766,510Institution2.77%21,109,795
1,521,314Institution2.38%19,701,016
1,473,744Institution2.31%19,084,985
836,223Institution1.31%9,992,865
405,387Institution0.64%5,630,825
280,703Institution0.44%3,635,104
185,975Institution0.29%2,222,401
155,121Institution0.24%2,008,817
158,845Institution0.25%1,898,198
134,915Institution0.21%1,873,969

FAQ

Who Owns Viridian Therapeutics (VRDN)?
According to the latest TipRanks data, approximately 12.73% of the company's stock is held by institutional investors, 33.29% is held by insiders, and 29.54% is held by retail investors.
    What percentage of Viridian Therapeutics (VRDN) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 12.73% of Viridian Therapeutics (VRDN) stock is held by institutional investors.
      What percentage of Viridian Therapeutics (VRDN) stock is held by retail investors?
      According to the latest TipRanks data, approximately 29.54% of Viridian Therapeutics (VRDN) stock is held by retail investors.
        Who owns the most shares of Viridian Therapeutics (VRDN)?
        Joseph Edelman owns the most shares of Viridian Therapeutics (VRDN).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis